Jonathan S. Goldberg

Dr. Jonathan S. Goldberg

Hematology | Oncology
90 South Bedford Road, 
Mount Kisco, NY 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
90 South Bedford Road, 
Mount Kisco, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jonathan Goldberg is a Hematologist and an Oncologist in Mount Kisco, New York. Dr. Goldberg is rated as an Experienced provider by MediFind in the treatment of Hereditary Pyropoikilocytosis. His top areas of expertise are Familial Prostate Cancer, Non-Hodgkin Lymphoma, Inflammatory Breast Cancer, and Angiosarcoma.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Mount Sinai Hospital
Residency
Memorial Sloan-Kettering Cancer Center
Specialties
Hematology
Oncology
Licenses
Internal Medicine in NY
Board Certifications
American Board Of Internal Medicine/Hematology
American Board Of Internal Medicine/Medical Oncology
Hospital Affiliations
Hofstra/Northwell School Of Medicine/Nursing
Northern Westchester Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

90 South Bedford Road, Mount Kisco, NY 10549
Other Locations
185 Route 312, Brewster, NY 10509

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Carboplatin, Etoposide, Atezolizumab
Study Phase: Phase 2
An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects With Non-Small Cell Lung Cancer
An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects With Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination With Either Venetoclax or Placebo in Subjects With Relapsed or Refractory Multiple Myeloma Who Are Sensitive or Naïve to Proteasome Inhibitors
A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination With Either Venetoclax or Placebo in Subjects With Relapsed or Refractory Multiple Myeloma Who Are Sensitive or Naïve to Proteasome Inhibitors
Enrollment Status: Completed
Publish Date: August 22, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
View 8 Less Clinical Trials

3 Total Publications

A case of testicular diffuse large B-cell lymphoma with late relapse in the skin: the critical role of comparative phenotypic, clonality, and cytogenetic testing.
A case of testicular diffuse large B-cell lymphoma with late relapse in the skin: the critical role of comparative phenotypic, clonality, and cytogenetic testing.
Journal: Leukemia & lymphoma
Published: July 17, 2024
Similar Doctors
Experienced in Hereditary Pyropoikilocytosis
Dr. Ravi S. Shah
Hematology
Experienced in Hereditary Pyropoikilocytosis
Dr. Ravi S. Shah
Hematology

WPH Highland Medical Group

2 Longview Avenue, 5th Floor, 
White Plains, NY 
 (27.8 miles away)
845-480-7440
Languages Spoken:
English
See accepted insurances

Ravi Shah is a Hematologist in White Plains, New York. Dr. Shah is rated as an Advanced provider by MediFind in the treatment of Hereditary Pyropoikilocytosis. His top areas of expertise are Childhood Iron Deficiency Anemia, Multiple Carboxylase Deficiency, Folate Deficiency, and Vitamin B12 Deficiency Anemia.

Experienced in Hereditary Pyropoikilocytosis
Dr. Vinit G. Karur
Hematology Oncology | Hematology | Oncology
Experienced in Hereditary Pyropoikilocytosis
Dr. Vinit G. Karur
Hematology Oncology | Hematology | Oncology

The Westchester Medical Practice PC

1980 Crompond Rd, 
Cortlandt Manor, NY 
 (16.2 miles away)
914-737-9000
Languages Spoken:
English
See accepted insurances

Vinit Karur is a Hematologist Oncology specialist and a Hematologist in Cortlandt Manor, New York. Dr. Karur is rated as an Advanced provider by MediFind in the treatment of Hereditary Pyropoikilocytosis. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, and Bone Marrow Aspiration.

Experienced in Hereditary Pyropoikilocytosis
Dr. Alfred Cretella
Oncology | Hematology Oncology
Experienced in Hereditary Pyropoikilocytosis
Dr. Alfred Cretella
Oncology | Hematology Oncology
11 Grove St, Booth House, 
New Milford, CT 
 (15.6 miles away)
860-354-5544
Languages Spoken:
English

Alfred Cretella is an Oncologist and a Hematologist Oncology provider in New Milford, Connecticut. Dr. Cretella is rated as an Advanced provider by MediFind in the treatment of Hereditary Pyropoikilocytosis. His top areas of expertise are Pleuropulmonary Blastoma, Squamous Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Goldberg's expertise for a condition
ConditionClose
      View All 40 Advanced Conditions
      View All 109 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile